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ATP is released in a vesicularmanner fromnerve terminalsmainly at higher stimulation frequencies. There is a robust expression ofATP
(P2) receptors in the brain, but their role is primarily unknown.We report that ATP analogs biphasically modulate the evoked release of
glutamate frompurified nerve terminals of the rat hippocampus, the facilitation beingmediated by P2X1 , P2X2/3 , andP2X3 [antagonized
by 8-(benzamido)naphthalene-1,3,5-trisulfonate and 2,3-O-(2,4,6-trinitrophenyl)-ATP] and the inhibition by P2Y1, P2Y2 , and/or P2Y4
[antagonizedby reactive blue 2 and2deoxy-N 6-methyladenosine-3,5-bisphosphate andmimickedbyP1-(urinine 5-),P4-(inosine 5-)
tetraphosphate and 2-methylthio-ADP] receptors. The combination of single-cell PCR analysis of rat hippocampal pyramidal neurons,
Western blot analysis of purified presynaptic active zone fraction, and immunocytochemical analysis of hippocampal glutamatergic
terminals revealed that the P2 receptors expressed in glutamatergic neurons, located in the active zone and in glutamatergic terminals,
were precisely P2X1, P2X2 , and P2X3 subunits and P2Y1, P2Y2 , and P2Y4 receptors. This provides coincident functional and molecular
evidence that P2 receptors are present and act presynaptically as a modulatory system controlling hippocampal glutamate release.
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Introduction
Stimulation of nerve terminals triggers a release of ATP (Sperla´gh
and Vizi, 1996), which can act directly as an extracellular signal-
ing molecule through activation of P2 (ATP) receptors (Ralevic
and Burnstock, 1998) or be converted through ectonucleotidases
into adenosine (Zimmermann and Braun, 1996), with subse-
quent activation of P1 (adenosine) receptors (Fredholm et al.,
2005). The P2 receptor family comprises seven ionotropic P2X
receptors subunits (P2X1–7), forming either homomeric or het-
eromeric receptors (North, 2002), and eight metabotropic P2Y
receptors (P2Y1,2,4,6,11,12,13,14) (Lazarowski et al., 2003). The
brain displays a robust mRNA expression, an intense binding,
and immunoreactivity for both P2X and P2Y receptors in neuro-
nal and non-neuronal elements, although the role of central P2
receptors remains ill defined (for review, see Cunha and Ribeiro,
2000). Because an ATPergic contribution to synaptic transmis-
sion has only been demonstrated in few central synapses (for
review, see Cunha and Ribeiro, 2000; Pankratov et al., 2003), it
was proposed that P2 receptors act principally as presynaptic
modulators in the brain (Cunha and Ribeiro, 2000). This view is
supported by the observed localization of several P2X subunits
(for review, see Cunha and Ribeiro, 2000; Deuchars et al., 2001;
Dia´z-Herna´ndez et al., 2001) and P2Y receptors in brain nerve
terminals (Scha¨fer and Reiser, 1997; Simon et al., 1997) and by
functional studies indicating a biphasic P2 receptor modulation
of the release of several types of neurotransmitters in different
brain regions: inhibition via P2Y and facilitation via P2X recep-
tors (for review, see Cunha and Ribeiro, 2000).
However, it is difficult to unambiguously ascribe P2 receptor-
mediated effects to presynaptic modulation, because most func-
tional studies rely solely on the use of the limited number of P2
receptor ligands that have an insufficient selectivity (Ralevic and
Burnstock, 1998), and few attempts have been made to complement
the studies with molecular or morphological approaches to identify
the putative P2 receptors involved. Similarly, limited attempts are
made to exclude the involvement of adenosine (formed after extra-
cellular catabolism of ATP by ectonucleotidases) P1 receptors (Dun-
widdie et al., 1997; Cunha et al., 1998), which is particularly critical
when studying glutamatergic transmission, because adenosine effi-
ciently inhibits excitatory transmission (Fredholm et al., 2005). Fi-
nally, it is difficult to unequivocally ascribe the modulation of trans-
mitter release to a presynaptic mechanism, especially when using
slices or microdialysis, as a result of indirect circuit- or astrocyte-
mediated effects that lead to indirect modulation of synaptic func-
tion (Zhang et al., 2003).
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Accordingly, we used purified nerve terminals (which allows
isolating presynaptic effects) (Raiteri and Raiteri, 2000) to assess
whether P2 receptors could presynaptically control the evoked
release of glutamate. In parallel, functional and morphological
approaches were used to identify the receptor subtypes mediating
these effects and to demonstrate their presence in nerve termi-
nals. This combined use of molecular biological, immunological,
and pharmacological approaches enabled us to demonstrate that
ATP presynaptically modulates the evoked release of glutamate in
a biphasic manner through the activation of presynaptic facilita-
tory P2X1, P2X2/3, and P2X3 and inhibitory P2Y1, P2Y2, and P2Y4
receptors.
Materials andMethods
Animals used in all experiments. Male Wistar rats (6 – 8 weeks of age;
140 –160 g; Harlan Ibe´rica, Barcelona, Spain) were used throughout this
study and were handled according to European Union guidelines for use
of experimental animals, the rats being anesthetized under halothane
atmosphere before being killed by decapitation.
Glutamate release studies.The release of glutamate from rat hippocam-
pal nerve terminals prepared using a combined sucrose/Percoll centrif-
ugation protocol was performed as described previously (Lopes et al.,
2002). Briefly, hippocampal tissue was homogenized in a medium con-
taining 0.32 M sucrose, 1 mM EDTA, 0.1% free bovine serum albumin
(BSA), and 10 mM HEPES, pH 7.4. The homogenate was spun for 10 min
at 3000  g at 4°C and the supernatant spun again at 14,000  g for 12
min. The pellet (P2 fraction) was resuspended in 1 ml of 45% Percoll
(v/v) in Krebs’–HEPES–Ringer’s (KHR) medium [composed of the fol-
lowing (in mM): 140 NaCl, 1 EDTA, 5 KCl, 5 glucose, and 10 HEPES, pH
7.4] and spun again at 14,000  g for 2 min. Synaptosomes were then
removed from the top layer, washed once with KHR medium, and resus-
pended in a Krebs’ solution [composed of the following (in mM): 124
NaCl, 3 KCl, 1.25 NaH2PO4, 25 NaHCO3, 2 MgSO4, 2 CaCl2, and 10
glucose], which was gassed with a 95% O2 and 5% CO2 mixture. The
nerve terminals were equilibrated at 37°C for 10 min, loaded with 0.2M
[ 3H]glutamate for 5 min at 37°C, washed, layered over Whatman GF/C
filters (VWR, Lisbon, Portugal), and superfused (flow rate, 0.8 ml/min)
with Krebs’ solution for 20 min before starting collection of the superfu-
sate. The synaptosomes were stimulated with 20 mM K (isomolar sub-
stitution of NaCl by KCl in the Krebs’ solution) at 3 and 9 min after
starting sample collection (S1 and S2), triggering a release of tritium in a
Ca 2-dependent manner that is mostly [ 3H]glutamate, gauged by
HPLC (Lopes et al., 2002). Tested agonists were added 2 min before S2
onwards and their effect quantified by the modification of S2/S1 ratio
versus control (i.e., absence of agonist), whereas antagonists were added
from 10 min before starting sample collection onwards, and none of the
tested antagonists modified the S2/S1 ratio versus control. Radioactivity
was expressed in terms of disintegrations per second per milligram of
protein (becquerels per milligram) in each chamber (Lopes et al., 2002).
Intracellular calcium measurements. Intracellular calcium measure-
ments were performed in a partially purified synaptosomal fraction (P2)
from the rat hippocampus, essentially as described by Malva et al. (1995).
Synaptosomes (3 mg/ml) were incubated with 5 M fura-2 AM (Molec-
ular Probes, Alfagene, Lisbon, Portugal) and 0.02% Pluronic F-127
(Sigma, Sintra, Portugal) in an incubation medium [composed of the
following (in mM): 132 NaCl, 1 KCl, 1 MgCl2, 100 CaCl2, 1.2 H3PO4, 10
glucose, and 10 HEPES-Na, pH 7.4] with 0.1% fatty acid-free BSA for 20
min at 25°C. After this loading period, synaptosomes were pelleted, the
nonhydrolyzed probe was removed, and the synaptosomes placed in the
same medium plus 1.2 mM CaCl2. Synaptosomes were preincubated with
the antagonists 5 min before starting recording at 37°C, and agonists
were applied 50 s after starting recording and 150 s before stimulation
with 20 mM KCl. The fluorescence was monitored at 37°C, using a
computer-assisted Spex Industries (Edison, NJ) Fluoromax spectroflu-
orometer at 510 nm emission and double excitation at 340 and 380 nm,
using 5 nm slits. The calibration was made using 2.5M ionomycin (1.33
mM CaCl2; Rmax), at 500 s, and 24 mM EGTA (Rmin), at 600 s. The
fluorescence intensities were converted into [Ca 2]i values by using the
calibration equation for double excitation wavelength measurements
and taking the dissociation constant of the fura-2/Ca 2 complex as 224
nM (Grynkiewicz et al., 1985). Intracellular calcium transients were de-
termined by subtracting the [Ca 2]i basal value immediately before
stimulation from the [Ca 2]i value at 24 s after stimulation (peak
values).
Single-cell reverse transcription-PCR analysis of P2 receptor expression in
laser-dissected hippocampal pyramidal neurons. Coronal sections (6 and
10m) were obtained from frozen rat brains (between4.52 and2.80
mm from bregma). These sections were dehydrated in 100% ethanol and
rehydrated gradually (100 –50% ethanol), stained with Nissl stain, and
rehydrated again with xylene. CA1 or CA3 pyramidal cell bodies were
microdissected with laser with a microscope (LCM 210 PixCell II; Arc-
turus, Genetic Research Instrumentation, Essex, UK) with a spot size of
7.5 m (Lopes et al., 2003). The total RNA was then extracted according
to StrataPrep Total RNA micropep kit instructions from Stratagene
(La Jolla, CA) and subjected to reverse transcription (RT) and cDNA
amplification using a three prime end amplification PCR (TPEA-PCR)
protocol, as described previously (Richardson et al., 2000). Purification
of cDNA was achieved using QIA Quick PCR purification kit (Qiagen,
West Sussex, UK). Once obtained, samples of the preamplified cDNA
were subjected to 45 rounds of PCR in 20 l of 45 mM Tris-HCl, pH 8.1,
12.5% (w/v) sucrose, 12 mM (NH4)2SO4, 3.5 mM MgCl2, and 0.5 mM
deoxynucleotide triphosphates, with 100 ng of the forward and reverse
primers for each P2 receptor cDNA, detailed in Table 1. The cycling
conditions were 2.5 min at 92°C (denaturation), 1.5 min at 60°C (anneal-
ing), and 1 min at 72°C (extension). After amplification, the products
were separated on 2% agarose gels and visualized using ethidium bro-
mide. In all experiments, positive controls for the primers used were
electrophoresed in parallel to the gene-specific assays. These routinely
contained cDNA derived from 1 ng of whole-brain total RNA.
Subcellular fractionation of nerve terminals.The solubilization of extra-
synaptic, presynaptic active zone, and postsynaptic fractions from rat
hippocampal synaptosomes was performed according to the method
described previously (Phillips et al., 2001) with minor modifications. We
have confirmed previously that this subsynaptic fractionation method
allows a 90% effective separation of active zone [synaptosomal-
associated protein of 25 kDa (SNAP25)], postsynaptic density [postsyn-
aptic density-95 (PSD95)], and nonactive zone fraction (synaptophysin)
markers and can be used to access the subsynaptic distribution of recep-
tors (Pinheiro et al., 2003; Rebola et al., 2003). Briefly, hippocampi from
10 rats were homogenized at 4°C in 15 ml of isolation solution [0.32 M
sucrose, 0.1 mM CaCl2, 1 mM MgCl2, 0.1 mM phenylmethylsulfonylfluo-
ride (PMSF)]. The concentration of sucrose was raised to 1.25 M by
addition of 75 ml of 2 M sucrose and 30 ml of 0.1 mM CaCl2 and the
suspension divided into 10 ultracentrifuge tubes. The homogenate was
overlaid with 8 ml of 1.0 M sucrose, 0.1 mM CaCl2, and with 5 ml of
homogenization solution and centrifuged at 100,000 g for 3 h at 4°C.
Synaptosomes were collected at the 1.25/1.0 M sucrose interface, diluted
1:10 in cold 0.32 M sucrose with 0.1 mM CaCl2, and pelleted (15,000 g
for 30 min at 4°C). Pellets were resuspended in 1 ml of 0.32 M sucrose with
0.1 mM CaCl2 and a small sample taken for gel electrophoresis. Then,
synaptosomal suspension was diluted 1:10 in cold 0.1 mM CaCl2, and an
equal volume of 2 solubilization buffer (2% Triton X-100, 40 mM Tris,
pH 6.0) was added to the suspension. The membranes were incubated for
30 min on ice with mild agitation and the insoluble material (synaptic
junctions) pelleted (40,000  g for 30 min at 4°C). The supernatant
(extrasynaptic fraction) was decanted and proteins precipitated with 6
vol of acetone at 20°C and recovered by centrifugation (18,000 g for 30
min at 15°C). The synaptic junctions pellet was washed in pH 6.0 solu-
bilization buffer, resuspended in 10 ml of 1% Triton X-100 and 20 mM
Tris, pH 8.0, incubated for 30 min on ice with mild agitation, centrifuged
(40,000 g for 30 min at 4°C), and the supernatant (presynaptic active
zone fraction) processed as above. PMSF (1 mM) was added to the sus-
pension in all extraction steps. The pellets from the supernatants and the
final insoluble pellet (postsynaptic density fraction) were solubilized in
5% SDS, the protein concentration determined, and the samples added
to a 1⁄6 volume of 6 SDS-PAGE sample buffer for Western blot analysis.
Western blot analysis.The P2X1–7 or P2Y1,2,4,6,11,12 receptors immuno-
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reactivity was evaluated by Western blot analysis as described previously
(Rebola et al., 2003) using antibodies against P2X1 (1:500), P2X2 (1:
1000), P2X3 (1:300), P2X4 (1:500), P2X5 (1:100), P2X6 (1:100), P2X7
(1:10,000), P2Y1 (1:200), P2Y2 (1:500), P2Y4 (1:500), P2Y6 (1:300),
P2Y11 (1:500), and P2Y12 (1:200). This analysis was conducted in the
purified presynaptic active zone, postsynaptic density, and extrasynaptic
fractions of rat hippocampal nerve terminals for all P2 receptors. To
validate the antibodies, their immunoreactivities were tested in mem-
branes of either human embryonic kidney 293 (HEK293) cells transiently
expressing each P2X receptor subunits (P2X1–7) or human astrocytoma
1321N1 cells stably transfected with the cDNAs encoding for P2Y1,2,4,6,11
(see methods below). The immunoreactivity control of the antibody
against P2Y12 receptor was evaluated using rat platelet membranes, pre-
pared as described previously (Sugidachi et al., 2001), which have a high
density of this receptor (Ralevic and Burnstock, 1998).
Expression of P2X receptors in HEK293 cells and P2Y receptors in human
astrocytoma 1321N1 cells. cDNAs encoding for each P2X receptor
(P2X1–7) were donated by A. North (University of Sheffield, Sheffield,
UK). The HEK293 cells were transiently transfected with the cDNAs
using lipofectamine (Invitrogen, Alfagene). cDNA (0.4 g) was mixed
with 5 l of lipofectamine in 50 l of Opti-MEM I reduced serum me-
dium (Invitrogen). After 15– 45 min of incubation to allow the formation
of DNA–liposome complexes, this mixture was overlaid onto 50 – 80%
confluent cells plated in 100 mm dishes and maintained in DMEM with
10% heat-inactivated fetal calf serum (FCS) for 24 h. The cells were then
washed twice with PBS medium [containing the following (in mM): 137
NaCl, 2.7 KCl, 1.8 KH2PO4, 10 NaH2PO4, pH 7.4], collected in a hypo-
tonic lysis buffer [containing the following (in mM): 25 HEPES, 2 MgCl2,
1 EDTA, 1 EGTA, pH 7.4], sonicated, and subjected to low-speed cen-
trifugation to remove organelles and nuclei. The protein concentration
was determined and the samples were added to a 1⁄6 vol of 6 SDS-PAGE
sample buffer for Western blot analysis.
Human astrocytoma 1321N1 cells stably transfected with cDNAs en-
coding for P2Y1, P2Y2, P2Y4, P2Y6, or P2Y11 were donated by J. M.
Boeynaems (University of Brussels, Brussels, Belgium). Cells were main-
tained in DMEM nutrient mix supplemented with 10% FCS, 1% mixture
of streptomycin (100 U/ml)/penicillin (200 U/ml) (Sigma), and 0.5
mg/ml of geneticin G 418 sulfate (Calbiochem, VWR) in a water-
saturated atmosphere of 95% O2 and 5% CO2 at 37°C and passaged when
confluent. Wild-type cells were maintained in the same medium but
without Geneticin G 418 sulfate. The preparation of membranes and
determination of protein concentration for Western blot analysis was
performed as described for HEK293 cells.
Immunocytochemical analysis in rat hippocampal nerve terminals. For
immunocytochemical analysis, hippocampal synaptosomes were ob-
tained through a discontinuous Percoll gradient, as described previously
(Dia´z-Herna´ndez et al., 2001; Rodrigues et al., 2005). This procedure for
preparation of the synaptosomes is crucial to reduce the amount of
postsynaptic density material. In fact, immunocytochemical analysis of
the synaptosomes obtained with this discontinuous Percoll gradient
showed that 1% of the synaptophysin-positive elements were labeled
by an anti-PSD95 antibody (data not shown).
These hippocampal synaptosomes were placed onto coverslips coated
previously with poly-L-lysine, fixed with 4% paraformaldehyde for 15
min, and washed twice with PBS medium. The synaptosomes were per-
meabilized in PBS with 0.2% Triton X-100 for 10 min and then blocked
for 1 h in PBS with 3% BSA and 5% normal rat serum. The synaptosomes
were then washed twice with PBS and incubated with rabbit anti-P2X1
(1:500), anti-P2X2 (1:1000), anti-P2X4 (1:500), anti-P2X7 (1:10,000),
anti-P2Y2 (1:500), anti-P2Y4 (1:500), anti-P2Y11 (1:500), or anti-P2Y12
(1:200) receptors or goat anti-P2X3 (1:300), anti-P2X5 (1:100), anti-
P2X6 (1:100), anti-P2Y1 (1:200), or anti-P2Y6 (1:300) receptors and
guinea-pig anti-vesicular glutamate transporters type 1 (vGluT1; 1:5000)
and anti-vGluT2 (1:5000) for 1 h at room temperature. The synapto-
somes were then washed three times with PBS with 3% BSA and incu-
bated for 1 h at room temperature with AlexaFluor-488 (green)-labeled
donkey anti-goat or goat anti-rabbit IgG antibodies and AlexaFluor-598
(red)-labeled goat anti-guinea pig IgG antibodies (1:200 for all). After
washing and mounting on slides with Prolong Antifade, the preparations
were visualized in a Zeiss (Hitec, Sintra, Portugal) Axiovert 200 inverted
fluorescence microscope equipped with a cooled CCD camera and ana-
lyzed with MetaFluor 5.0 software. Each coverslip was analyzed by count-
ing three different fields and in each field a total amount of 500 individ-
ualized elements.
Statistics. The values presented are mean SEM of n experiments. To
test the significance of the effect of a drug versus control, an unpaired
Student’s t test was used.
Antibodies. The antibodies against P2X1, P2X2, P2X4, P2X7, P2Y2,
P2Y4, and P2Y12 receptors were from Alomone Labs (Jerusalem, Israel);
against P2X3, P2X5, P2X6, P2Y1, and P2Y6 receptors were from Santa
Cruz Biotechnology (Santa Cruz, CA); against P2Y11 receptor was from
Zymed (Quelug, Portugal); the antibodies against vGluT1 and vGluT2
were from Chemicon Europe (Southampton, UK); mouse anti-
synaptophysin and mouse anti-SNAP25 were from Sigma; and mouse
anti-PSD95 was from Upstate Biotechnology (Lake Placid, NY). All sec-
ondary antibodies for immunocytochemical analysis were purchased
from Molecular Probes (Alfagene). All secondary alkaline phosphatase-
tagged antibodies for Western blot were purchased to Amersham
Biosciences (Carnaxide, Portugal).
Drugs. 1,3-Dipropyl-8-cyclopentyladenosine (DPCPX), ,-methyl-
eneATP (,-MeATP), ,-ImidoATP (,-ImATP), suramin, brilliant
blue G, and pyridoxal phosphate-6-azo(benzene-2,4-disulfonic acid)
(PPADS) were from Sigma; 8-(benzamido)naphthalene-1,3,5-trisulfonate
(NF023), 2deoxy-N6-methyladenosine-3,5-bisphosphate (MRS2179),
reactive blue 2 (RB2), 2-3-O-(4-benzoylbenzoyl)-ATP (Bz-ATP), 2,3-O-
(2,4,6-trinitrophenyl)-ATP (TNP-ATP), 2-methylthio-ADP, and 4-(2-[7-
amino-2-(2-furyl)]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol
(ZM241385) were purchased from Tocris Cookson (Bristol, UK); P1,P3-
di(uridine 5-) triphosphate (INS415) and P1-(urinine 5-),P4-(inosine 5-)
tetraphosphate (INS45973) were provided by J. L. Boyer (Inspire Pharma-
ceuticals, Durham, NC). All drug stock solutions were made in water at a
concentration of 10 mM and diluted directly into the superfusion or batch
solution to the appropriate final concentration. [3H]glutamate (specific ac-
tivity, 45 Ci/mmol) was from Amersham Biosciences.
Results
ATPmodulates the evoked release of glutamate in a
biphasic manner
To assess the effect of P2 receptor activation on the evoked release
of glutamate from rat hippocampal nerve terminals, we tested
two stable ATP analogs, ,-ImATP (a nonselective P2 receptor
agonist) and,-MeATP (a selective agonist of P2 receptors con-
taining P2X1 and P2X3 subunits), because they are poor sub-
strates of both the ectonucleotidases catabolism and ectoprotein
kinases (Ralevic and Burnstock, 1998). The chemical stimulation
with 20 mM K for 30 s of the superfused hippocampal synapto-
somes that had been loaded previously with [ 3H]glutamate trig-
gered a Ca 2-dependent release of [ 3H]glutamate that repre-
sented 90% of the total tritium released (gauged by HPLC),
which was considered to represent the evoked release of gluta-
mate (Lopes et al., 2002). Two periods of chemical stimulation
(S1 and S2), separated by a 6 min interval, produced a similar
evoked release of glutamate (Fig. 1A) with an S2/S1 ratio of 0.88
0.03 (n  16). ,-ImATP (present only in S2) caused a
concentration-dependent biphasic effect in the evoked release of
glutamate: at the lower concentrations tested, 10 and 30 M,
,-ImATP inhibited glutamate release by 42.9 7.1% (n 4)
and 20.0  4.1% (n  4), respectively, whereas 60 and 100 M
,-ImATP facilitated glutamate release by 46.9 8.7% (n 4)
and 17.6 4.0% (n 4) (Fig. 1B). When we tested ,-MeATP,
only facilitatory effects were observed in the concentration range
tested (10 –100 M), with a maximal facilitatory effect of 31.4
5.8% (n 4) observed at 60 M of ,-MeATP (Fig. 1B).
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The biphasic effects of ATP are mediated by P2 receptors
The next necessary step was to test whether these effects of ATP
analogs on glutamate release were mediated through activation of
P2 receptors or through adenosine (P1) receptors after extracel-
lular catabolism of ATP analogs by the ectonucleotidase pathway
(Dunwiddie et al., 1997; Cunha et al., 1998). For that purpose, we
tested the ability of P2 and P1 receptor antagonists to modify the
effects of ,-ImATP and ,-MeATP. Neither the adenosine
A2A receptor antagonist ZM241385 (50 nM) nor the adenosine A1
receptor antagonist DPCPX (50 nM) significantly ( p  0.05)
modified the modulatory effects of ,-MeATP or ,-ImATP
(Fig. 1C,D). In contrast, these effects were abolished by the P2
receptor antagonists PPADS (20 M) or suramin (75 M) (Fig.
1C,D). These results indicate that both the facilitatory effect of
,-MeATP and the facilitatory and inhibitory effects of ,-
ImATP on the evoked release of glutamate were mediated
through the activation of P2 rather than P1 receptors. It should be
noted that DPCPX, ZM241385, PPADS, or suramin alone did not
cause any effect on the evoked release of glutamate nor on the
S2/S1 ratio, in agreement with the expected absence of tonic ef-
fects of endogenously released modulators in superfused synap-
tosomes. This is probably because any released substance was
effectively washed out by superfusion using a flow rate of 0.8
ml/min (Raiteri and Raiteri, 2000).
The inhibitory effects of ATP are mediated by P2Y receptors,
whereas the facilitatory effects are mediated by P2X receptors
As illustrated in Figure 2A, the facilitatory effect of 60 M ,-
ImATP was reversed in the presence of the selective P2X1,2/3,3
receptor antagonist NF023 (10M) (Soto et al., 1999), whereas it
was not modified ( p 0.05) by either the P2Y receptor antago-
nist RB2 (10 M) or the selective P2Y1 receptor antagonist
MRS2179 (10M) (Boyer et al., 2002). Furthermore, in the pres-
ence of another P2X1–3-selective antagonist, TNP-ATP (100 nM)
(North, 2002), the facilitation by ,-MeATP (60 M) of the
evoked release of glutamate was abolished (3.4  5.5%; n  5;
p  0.05). On the other hand, the inhibition caused by 10 M
,-ImATP was not modified ( p 0.05) by NF023 (10M), was
attenuated ( p 0.05) by MRS2179 (10M), and prevented ( p
0.05) by RB2 (10 M) (Fig. 2B). This suggests that P2X receptors
were responsible for the facilitatory effects whereas P2Y receptors
mediate the inhibitory effect of ATP analogs on the evoked re-
lease of glutamate.
Activation of P2X and P2Y receptors also biphasically
modulate the evoked [Ca2]i transients
The release of neurotransmitters is triggered by the influx of
Ca 2 in the active zone of nerve terminals and the presynaptic
modulation of neurotransmitter release often involves the con-
trol of this Ca 2 entry, either directly (through ionotropic recep-
tors) or indirectly through modulation of calcium channels
(Khakh and Henderson, 2000). Thus, we tested the effect of 30
and 60 M ,-ImATP on the evoked calcium transients, con-
centrations that had caused inhibitory and facilitatory effects,
respectively, on the evoked release of glutamate. Hippocampal
nerve terminals were stimulated with 20 mM K (as in the previ-
ous experiments), resulting in an increase in [Ca 2]i of 331 10
nM over a basal value of 212 6 nM. To exclude the involvement
of P1 receptors, all experiments were performed in the presence
of ZM241385 (50 nM) and DPCPX (50 nM). As for the control of
glutamate release, ,-ImATP modulated [Ca 2]i transients in a
biphasic manner (Fig. 3A): ,-ImATP (60 M) facilitated
[Ca 2]i transients by 14.3 1.7% (n 6), and ,-ImATP (30
M) inhibited [Ca 2]i transients by 11.0 2.6% (n 6). Despite
their low amplitude, which is expected based on the exponential
relationship between [Ca 2]i transients and neurotransmitter re-
lease (Augustine, 2001), it is possible to pharmacologically char-
acterize the receptors involved, as performed previously for other
Figure 1. The ATP analogs,-ImATP and,-MeATP biphasically modulate the evoked
release of glutamate from rat hippocampal nerve terminals through activation of P2 receptors.
A, Time course of tritium release from rat hippocampal synaptosomes challenged with two
periods of stimulation with 20 mM K for 30 s (S1 and S2), as indicated by the bars above the
abscissa. This representative experiment shows that 60 M ,-ImATP (filled symbols), ap-
plied through the superfusate in the test chambers 2min before S2 (as indicated by the top bar),
increases glutamate release in S2. B, The nonselective P2X/P2Y receptors agonist,-ImATP
caused a concentration-dependent biphasic effect on the evoked release of glutamate, inhibit-
ing at the lower (10–30M) and facilitating at higher (60–100M) concentrations, whereas
the P2X-prefering agonist ,-MeATP only facilitated the evoked release of glutamate at all
concentrations tested. *p 0.05 compared with 0%. C, The facilitatory effects of both 60M
,-ImATP and 60M,-MeATP were not modified in the presence of 50 nM ZM241385 (a
selective antagonist of adenosine A2A receptors) but were prevented by 20M PPADS (nonse-
lective P2 receptor antagonist).D, The inhibitory effect of 30M,-ImATPwas notmodified
in the presence of 50 nM DPCPX (selective antagonist of adenosine A1 receptor) but were pre-
vented by both 75M suramin and 20M PPADS. *p 0.05 comparedwith the effects of ATP
analogs. The results are mean SEM of four to six experiments.
Figure 2. The facilitatory effect of ATP analogs is mediated by P2X receptors, whereas the
inhibitory effect is mediated by P2Y receptors. A, The facilitatory effect of 60M ,-ImATP
was reverted in the presence of NF023 (10 M; a selective P2X1, P2X2/3, and P2X3 receptor
antagonist) and notmodified by either RB2 (10M; a P2Y receptor antagonist) orMRS2179 (10
M; a selective P2Y1 receptor antagonist).B, The inhibitory effect of 10M,-ImATPwasnot
modified by NF023 but was prevented by RB2 and attenuated by MRS2179. *p 0.05 com-
pared with the first bar from left in A and B. The results are mean  SEM of four to six
experiments.
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presynaptic receptors (Malva et al., 1995;
Dia´z-Herna´ndez et al., 2001). Both the fa-
cilitatory and inhibitory effects of ,-
ImATP were prevented by PPADS (20
M), indicating the involvement of P2 re-
ceptors. Furthermore, the facilitatory ef-
fect of 60 M ,-ImATP was attenuated
( p  0.05) by NF023 (10 M) but not by
10 M RB2 (Fig. 3B), whereas the inhibi-
tory effect of 30M,-ImATP was atten-
uated ( p 0.05) by 10M RB2 but not by
10M NF023 (Fig. 3C). This reinforces the
idea that the presynaptic biphasic effects of
ATP analogs are mediated by inhibitory
P2Y and facilitatory P2X receptors.
P2X7 receptor does not presynaptically
control glutamate release
It was described recently that the P2X7 re-
ceptor is targeted to glutamatergic nerve
terminals in different brain regions (Deuchars et al., 2001; Miras-
Portugal et al., 2003), including the hippocampus (Armstrong et
al., 2002; Sperla´gh et al., 2002). However, some studies cast
doubts on the selectivity of the most commonly used antibodies
against P2X7 receptors (Sim et al., 2004), and it has been shown
that purported P2X7 receptor agonists might also indirectly acti-
vate adenosine A1 receptors (Kukley et al., 2004). We report that
Bz-ATP (5M; a concentration selective for P2X7 or P2X1 recep-
tor activation) (North, 2002) facilitated by 48.5 11.2% (n 4)
the evoked release of glutamate. This facilitatory effect of Bz-ATP
was not modified ( p 0.05) by brilliant blue G (200 nM; 51.4
11.5% facilitation; n  4) but was prevented ( p  0.05) by
suramin (75 M; 5.7  7.6% inhibition; n  4), indicating the
involvement of P2X1 receptors and ruling out the involvement of
P2X7 receptors that are sensitive to brilliant blue G (especially in
the rat) and insensitive to suramin (North, 2002).
Pharmacological identification of P2Y receptors inhibiting
glutamate release
The ability of MRS2179 to attenuate (but not abolish like RB2)
the inhibition of glutamate release by ATP analogs indicates that
P2Y1 receptors as well as other P2Y receptors are involved. Ac-
cordingly, a P2Y2,4 receptor agonist synthesized by Inspire Phar-
maceuticals, INS45973 (0.5 M), inhibited glutamate release by
26.2  6.0% (n  4), whereas a selective P2Y6 receptor agonist,
INS415 (2M), was devoid of effects (1.5 7.7%; n 4) (Shaver
et al., 2005). Furthermore, the P2Y1/12/13-selective agonist
2-methylthio-ADP (1 M) inhibited by 34.7 6.4% (n 5; p
0.05) the evoked release of glutamate, an effect that was abolished
( p  0.05) in the presence of 10 M MRS2179 (3.8  6.1%
inhibition; n 6). These results suggest that, in addition to P2Y1
receptors, P2Y2 and/or P2Y4 receptors, but not P2Y6, P2Y12, or
P2Y13 receptors, are also involved in the inhibitory control of the
evoked release of glutamate from rat hippocampal nerve
terminals.
Identification of P2 receptors expressed in single
hippocampal pyramidal neurons
The general lack of subtype-selective P2 receptors ligands limits
the pharmacological characterization of the P2 receptors in-
volved in the control of glutamate release. Thus, we decided to
define which receptors are expressed in single pyramidal neurons
(i.e., glutamatergic neurons) to short-list the candidate P2 recep-
tors likely to be involved. We first confirmed the quality of the
mRNA extracted from single pyramidal neurons by the lack of
PCR product corresponding to an intronic marker (Fig. 4A, lane
A), which was present when analyzing genomic DNA (1 ng) (Fig.
4A, lane B). We then selected for analysis 12 laser-dissected py-
ramidal neurons for which the recovered cDNA obeyed the cri-
teria expected for glutamatergic neurons [i.e., presence of PCR
products corresponding to a house-keeping gene, ribosomal pro-
tein L11, and to the NR1 subunit of NMDA receptors and ab-
sence of PCR products corresponding to glutamate decarboxyl-
ase (GAD; a marker of GABAergic neurons) and to glial fibrillary
acidic protein (GFAP; a marker of glial cells)] (Fig. 4B). In these
12 samples, we detected PCR products corresponding mainly to
P2X3 (6 of 12) but also P2X4 (3 of 12), P2X1, and P2X2 (2 of 12)
receptor subunits. We failed to detect in any of the neurons tran-
scripts for P2X5, P2X6, and P2X7, despite our care to use three
different sets of primers (Table 1). In relationship to P2Y recep-
tors, we detected PCR products corresponding predominantly to
P2Y1 (9 of 12) but also for P2Y2 (6 of 12), P2Y4, P2Y6, P2Y11, and
P2Y12 (2 of 12).
Combining these molecular biology data with the pharmacol-
ogy data, P2X1, P2X2/3, and P2X3 receptors emerge as the leading
candidates to mediate P2 receptor facilitation, and P2Y1, P2Y2,
and eventually P2Y4 receptors stand as the most likely candidates
to mediate P2 receptor inhibition, although P2Y11 receptor
should also be considered.
Identification of P2X and P2Y receptors located in the
presynaptic active zone
The ability of P2X receptors to facilitate and P2Y receptors to
inhibit the evoked release of glutamate allows the prediction that
the candidate receptors to mediate these effects should be located
in the active zone of rat hippocampal nerve terminals. We took
advantage of a recently described fractionation procedure to pu-
rify the presynaptic active zone (Phillips et al., 2001) to test by
Western blot analysis which P2 receptors were present there. We
have previously validated the technique for separation of the pre-
synaptic active zone from the postsynaptic density and from
other presynaptic proteins not located in synapses, which allows a
90% efficiency of separation of these fractions (Fig. 5A), and we
have confirmed its usefulness to evaluate the subsynaptic distri-
bution of both ionotropic (Pinheiro et al., 2003) and metabo-
tropic (Rebola et al., 2003) receptors.
We report that the most abundant P2X receptor subunits en-
Figure 3. ,-ImATP modulates the evoked [Ca 2]i transients in a biphasic manner through inhibitory P2Y and facilitatory
P2X receptors in rat hippocampal nerve terminals. A, Representative experiment of the increase and decrease of the K (20
mM)-evoked [Ca 2]i caused by,-ImATP at 60 and 30M, respectively. All experiments were performed in the presence of 50
nM ZM241385 and 50 nM DPCPX to exclude P1 receptor-mediated effects. B, The facilitatory effect of 60 M ,-ImATP was
prevented by PPADS (20M; a nonselective P2 receptor antagonist) and by NF023 (10M; a selective antagonist of P2X1, P2X2/3,
and P2X3 receptors) and not modified by RB2 (10M; a preferring antagonist of P2Y receptors). C, The inhibitory effect of 30M
,-ImATP was not modified by NF023 but was prevented by PPADS and attenuated by RB2. The percentage variations of
[Ca 2]i are relative to control values (B, C). *p 0.05 comparedwith 0%. **p 0.05 comparedwith first bar from left inB and
C. The results are mean SEM of four to six experiments.
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riched in the presynaptic active zone fraction are P2X1, P2X2,
P2X3, P2X5, and P2X6 (Fig. 5B). P2X1, P2X5, and P2X6 are also
abundantly located in the postsynaptic density, and P2X3, P2X4,
and P2X6 are abundantly located extrasynaptically in nerve ter-
minals. Concerning the tested P2Y receptors, we report that they
are all mainly located in the postsynaptic density, except the
P2Y11 receptor that has a predominant extrasynaptic localization
(Fig. 5C). The most abundant P2Y receptors in the presynaptic
active zone were P2Y1, P2Y2, and P2Y4 receptors, whereas P2Y6 and
P2Y12 were nearly exclusively found in the postsynaptic density. The
relative subsynaptic distribution of all P2X subunits and P2Y recep-
tors in presynaptic, postsynaptic, and extrasynaptic fractions is de-
tailed in Table 2.
Identification of P2X and P2Y receptors located in
hippocampal glutamatergic terminals
Because the fractionation procedure used above does not allow
purification of only the synaptic fractions from glutamatergic
terminals, we undertook a complementary double immunocyto-
chemistry study in single nerve terminals aimed to identify the
P2X and P2Y receptors located in particular in glutamatergic
terminals, identified as the terminals labeled with antibodies
against vesicular glutamate transporters type 1 and type 2 (see
Fig. 6A as an example for P2X3 of the strategy used to identify its
presence in glutamatergic terminals). vGluT1 and/or vGluT2 im-
munopositive nerve terminals comprised 38.6 0.9% (n 3) in
the total population of hippocampal nerve terminals, identified
as synaptophysin-immunoreactive elements. As presented in Fig-
ure 6B, the P2X receptor subunits most frequently located in
glutamatergic terminals were P2X1, P2X2,
P2X3, and P2X4 receptor subunits (Fig.
6B, filled bars). The P2Y receptors most
frequently located in glutamatergic termi-
nals were P2Y1, P2Y2, and P2Y4 receptors
(Fig. 6B, open bars).
Crossing this double immunocyto-
chemistry data with the data obtained in
the subsynaptic fractionation of the pre-
synaptic active zone, it can conclude that
P2X1, P2X2, and P2X3 receptor subunits
and P2Y1, P2Y2, and P2Y4 receptors are the
most abundantly located in the presynap-
tic active zone membrane and also the
most frequently found in glutamatergic
terminals. These receptors are precisely
those that are most expressed in pyramidal
neurons and the leading candidates based
on the pharmacological characterization
of the evoked release of glutamate.
Discussion
The present study first shows that ATP can
biphasically modulate (i.e., both facilitate
and inhibit) the evoked release of gluta-
mate from rat hippocampal nerve termi-
nals through the activation of P2X and
P2Y receptors, respectively. However, the
main finding is the identification of the
presynaptic P2X and P2Y receptors that
are responsible for these inhibitory and fa-
cilitatory effects. By combining the data
obtained in pharmacological studies,
single-cell PCR, Western blot after sub-
synaptic fractionation, and double immu-
nocytochemistry in single nerve terminals, we concluded that the
facilitatory effects are caused by P2X1, P2X2/3, and P2X3 receptors
and the inhibitory effects are mediated by P2Y1, P2Y2, and/or
P2Y4 receptors.
These conclusions are based on the observation that the ATP
analog ,-ImATP modulated the evoked release of glutamate
from rat hippocampal nerve terminals in a concentration-
dependent biphasic manner, inhibiting at the lower concentra-
tions tested (10 –30 M) and facilitating at concentration of 60 –
100 M. These biphasic effects are mediated through P2, but not
adenosine P1, receptor activation because the selective antago-
nists of adenosine A1 or A2A receptors (DPCPX or ZM241385)
failed to modify the effects of ,-ImATP, which were prevented
by the P2 receptor antagonists PPADS and suramin. The phar-
macological characterization was developed to show that the fa-
cilitatory effects are mediated by P2X receptors and the inhibitory
effects by P2Y receptors because: (1) ,-MeATP, an agonist of
P2X1- and P2X3-containing receptors, only facilitated glutamate
release at all concentrations tested (10 –100 M); (2) the selective
antagonists of P2X1, P2X2/3, and P2X3 receptors, NF023 and
TNP-ATP, prevented the facilitatory (but not the inhibitory) ef-
fect of ATP analogs; (3) the selective P2Y and P2Y1 antagonists
RB2 and MRS2179 prevented and attenuated, respectively, the
inhibitory (but not the facilitatory) effect of ATP analogs. This is
reinforced by the fact that a similar pharmacological profile was
obtained both for the release of glutamate and for calcium tran-
sients in the same hippocampal nerve terminals. Furthermore,
apart from P2Y1 receptors, we could define the involvement of
Figure 4. RT-PCR identification of the P2 receptors expressed in single pyramidal neurons of the rat hippocampus. Individual
cell bodies of CA1 andCA3pyramidal neuronswere removedunder visualmicroscopic guidance fromaNissl-stained10-m-thick
hippocampal slice, using a laser dissection slot (7.5m). Every sample of mRNA extracted from the cytoplasmic contents har-
vested from single hippocampal pyramidal neurons was subjected to reverse transcription protocol and amplified using a TPEA.
They were then screened by PCR analysis, and the PCR products were resolved on 2–3% agarose gels and visualized by ethidium
bromide staining. A, No PCR product was observed in the cDNA samples corresponding to an intronic marker (lane A), which
indicates that all post-TPEA samples were DNA free. As positive controls, genomic DNA was always tested in parallel (lane B). B,
Every single cDNA sample obtained from the laser-dissected single neurons that matched the PCR criteria for obtaining a single
glutamatergic neuron [i.e., positive for a house-keeping gene (ribosomal protein L11) and a glutamatergic marker (NMDA
receptor 1 subunit) and negative for both a GABAergic (GAD) and astrocytic (GFAP) markers] was screened by gene-specific PCR
analysis for P2X subunits and P2Y receptors (B, bottom gels). In every assay, positive controls were performed using whole-brain
cDNA instead (B, top gels). All the primers used are detailed in Table 1. Rib. Prot. L11, Ribosomal protein L11.
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P2Y2 and P2Y4 receptors and exclude P2Y6 receptors, based on
the use of selective agonists provided by Inspire Pharmaceuticals,
disregard the involvement of P2Y12 and P2Y13 receptors, based
on the ability of MRS2179 to abolish the inhibition caused by
2-methylthio-ADP, and rule out the involvement of P2X7
receptors.
The lack of selective pharmacological tools to further narrow
the candidate P2 receptors led us to use alternative approaches to
identify the P2X and P2Y receptors presynaptically controlling
glutamate release. For that purpose, we used three different mo-
lecular approaches from the mRNA to the protein level. The ra-
tionale was the following: (1) the receptors should be expressed in
Table 1. PCR primers used for detection of P2 receptor mRNA in single hippocampal pyramidal neurons of both CA3 and CA1 areas
Name
Primers
PCR product (bp)Forward (5–3) Reverse (5–3)
Ribosomal protein L11 TTCTATGTGGTGCTGGGTAGG TTGCCTCCTCTTTGCTGATT 187
Glutamate decarboxylase ATCTTGCTTCAGTAGCCTTTGC TGTCTTCAAAAACACTTGTGGG 220
Glial fibrillary acidic protein CTGGGCAGGGTACAGG AAACAGGATGGACGCTTAAA 222
Intronic marker GCCTGCATTCATCTTCATCTGC AAAGGTGGAACTCGCCCGTTT 189
NMDA receptor subunit 1 TAGTGGCAGTGCTTCAGGG GTGACACCGGACTGGGGAG 178
ATP (P2) receptors
rP2X1 GTTCAGCATGAAGACAGGCA GAGTATAGATGTGTGAGGGGCC 136
rP2X2 TGTGACTGGGAAACAGAAACC AGGAGATGGCAGGGAACC 114
rP2X3 AAGAAGGGGCTGCTATTTCTGC AGGCATGCAAGGGGTAAAG 126
rP2X4 CTGGTGTGCTGGTTGGGCTG ACCTGAGAGAGCCTCCTTCC 152
rP2X5 ACTTAGGGAAGAGCAAACTCCC AGCAAGAGCTGAACTGCACA 156
rP2X6 AGGCTAGGGTGAAAGCAACA GCAGGAATATCAGGTTCTTTGG 201
rP2X7 1-TAAAGTTTGGATGTGGCTTGG 1-TCTGTGTGGTGTGTGGTGTGTG 156
2-AGACAAACAAAGTCACCCGG 2-GGTATACACCTGCCGGTCTGG 400
3-AGGAGCCCCTTATCAGCTCT 3-CATTGGTGTACTTGTCGTCC 711
rP2Y1 CCCTAACTATGATGCAGCTT GCTGCATCTTATCACCCT 151
rP2Y2 GCCACCTGACTCCCATGCAA CCGCTGAGCTAAATCCC 167
rP2Y4 GGGGACAAGTATCGAAACCA GCCCCTGCAGTTAGTTCCCTT 208
rP2Y6 GACACCTGTGTTTCGGGGAC CCTCTACAGGAGGGGCCTT 259
hP2Y11 ACTGGTGGTTGAGTTCCTGG TCAGGTGGGAGAAGCTGAGT 410
rP2Y12 CAGAAATTCCTTGATGAGCA ATGTGGTGATTTCCTTGGAG 175
Figure5. Subsynaptic distribution of P2X andP2Y receptors in thehippocampus.A, Selective antibodies for eachP2X andP2Y receptorswere testedbyWestern blot analysis in a fraction enriched
in the presynaptic active zone, in the postsynaptic density, in nerve terminals outside the active zone, and in the initial synaptosomal fraction fromwhich fractionation began. These fractions were
over 90% pure, as illustrated by the ability to recover the immunoreactivity for SNAP25 in the presynaptic active zone fraction, PSD95 in the postsynaptic density fraction, and synaptophysin (a
protein located in synaptic vesicles) in the extrasynaptic fraction.B, C,Western blots in these fractions evaluating the subsynaptic distribution of the immunoreactivity of the antibodies selective for
each P2X subunit and for each P2Y receptor tested (20–120g of protein of each fraction were applied to SDS-PAGE gels). To gauge the selectivity of the antibodies used, their immunoreactivity
were tested in membranes of HEK cells transiently transfected with cDNAs encoding for each P2X subunit (B) and of 1321N1 human astrocytoma cell line stably transfected with each P2Y receptor
(C). For P2Y12 receptor, rat platelet membranes were used as a positive control. Each blot is representative of at least three blots from different groups of animals with similar results. For each
fractionation procedure, Western blot analysis for the markers of each fraction was performed as illustrated in A to assess the efficiency of each fractionation. Pre, Presynaptic active zone; Post,
postsynaptic density; Extra, outside the active zone; Syn, synaptosomal.
Table 2. Relative subsynaptic distribution of P2X1–7 subunits and P2Y1,2,4,6,11,12 receptors in the presynaptic, postsynaptic, and extrasynaptic fractions
Subsynaptic
fraction P2X1 P2X2 P2X3 P2X4 P2X5 P2X6 P2X7 P2Y1 P2Y2 P2Y4 P2Y6 P2Y11 P2Y12
Presynaptic 42.4 2.8 75.1 1.4 47.0 1.4 22.6 1.2 55.4 1.7 35.4 1.6 22.4 4.8 28.5 1.5 23.1 1.5 44.3 2.6 5.0 0.7 0.8 0.3 0.6 0.2
Postsynaptic 54.5 3.1 24.0 1.4 14.6 0.7 17.1 2.0 44.1 1.8 33.9 2.4 72.8 4.9 70.3 1.3 53.0 0.8 55.0 2.5 94.5 0.6 0.5 0.2 98.6 0.4
Extrasynaptic 3.1 1.0 0.9 0.1 38.4 1.5 60.2 1.2 0.5 0.2 30.4 0.8 4.8 0.6 1.2 0.2 23.9 0.9 0.7 0.2 0.4 0.1 98.7 0.5 0.8 0.3
The data show relative average percentage of immunoreactivity (mean SEM) measured by densitometry of three different Western blots from different synaptosomal preparations from different animals.
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hippocampal glutamatergic neurons; (2) they should be located
in the active zone; (3) they should be located in glutamatergic
terminals. Only the receptor candidates fulfilling these three cri-
teria that also matched the pharmacological characterization
should be claimed to be involved in the control of glutamate
release. By single-cell RT-PCR, we detected mRNA expression in
glutamatergic neurons from CA1 and CA3 areas for P2X1, P2X2,
P2X3, and P2X4 subunits and P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, and
P2Y12 receptors. Looking at the subsynaptic distribution at the
protein level, we found that P2X1, P2X2, and P2X3 were enriched
in the presynaptic active zone, whereas P2Y1, P2Y2, and P2Y4
were the only tested P2Y receptors located at the presynaptic
active zone. Restricting the analysis to the glutamatergic nerve
terminals, double immunocytochemistry revealed that P2X1,
P2X2, P2X3, and P2X4 were present in a higher percentage of
glutamatergic nerve terminals (identified as vGluT1/2 positive),
whereas P2Y1, P2Y2, and P2Y4 were the most frequently found
P2Y receptors in glutamatergic terminals. Thus, combining the
data obtained in these molecular studies, the P2 receptors that are
expressed in glutamatergic cells, targeted to nerve terminals, and
located in the presynaptic active zone are P2X1, P2X2, and P2X3
subunits and P2Y1, P2Y2, and P2Y4 receptors. This is in total
agreement with the pharmacological characterization, thus con-
firming the involvement of P2X1, P2X2/3, and P2X3 receptors in
the facilitation and of P2Y1, P2Y2, and P2Y4 receptors in the
inhibition of hippocampal glutamate release.
This study constitutes the first attempt to thoroughly identify
which P2 receptors controlled glutamate release using combined
functional and molecular approaches, which yielded remarkably
coincident conclusions. The main conclusion that P2 receptors
presynaptically control the release of glutamate, together with the
morphological data indicating that a substantial proportion of
glutamatergic terminals are endowed with different subtypes of
P2 receptors (both P2X and P2Y), confirms our hypothesis that
P2 receptors play a major neuromodulatory role at the presynap-
tic level controlling the release of neurotransmitters rather than
acting postsynaptically (Cunha and Ribeiro, 2000). This provides
a logical explanation to reconcile the robust expression and den-
sity of P2 receptors in the hippocampus with the discrete contri-
bution of P2 receptors to synaptic transmission (Pankratov et al.,
1998; Mori et al., 2001). It was also interesting to conclude that
receptors for the same ligand (ATP) but with opposite effects
were present in hippocampal glutamatergic terminals, as re-
ported to occur in glutamatergic synapses of the rat medial habe-
nula nucleus (Price et al., 2003). In particular, ,-ImidoATP
caused biphasic effects on glutamate release over a narrow con-
centration range, in a manner analogous to that observed to oc-
cur for the biphasic P2X/P2Y receptor modulation of noradren-
aline release from the rat vas deferens (Queiroz et al., 2003). It
remains to be determined whether this prevalence of P2X
receptor-mediated facilitation over P2Y receptor-mediated inhi-
bition of hippocampal glutamate release with increasing concen-
trations of ATP analogs results from: (1) a greater efficiency of
glutamatergic P2X compared with P2Y receptors; (2) a greater
number of glutamatergic terminals equipped with a greater den-
sity of P2X compared with P2Y receptors; (3) an interaction be-
tween P2X and P2Y receptors so that the former would down-
regulate the later. The possible involvement of P2X1 and/or P2X3
receptors in this predominant P2X receptor-mediated facilita-
tion of hippocampal glutamate release at higher concentrations
of ATP analogs might also seem surprising in view of their fast
desensitizing kinetics observed in heterologous expression sys-
tems or when located postsynaptically (North, 2002). However,
like for P2X1–3 (present study) (Dia´z-Herna´ndez et al., 2001;
Queiroz et al., 2003), the activation of other presynaptic iono-
tropic receptors, such as kainate or nicotinic acetylcholine recep-
tors (Khakh and Henderson, 2000), also causes long-lasting non-
desensitizing presynaptic changes, in clear contrast with their fast
desensitizing properties when located outside nerve terminals,
for reasons still to be unraveled.
Finally, it still remains to be defined in what physiological
conditions might this P2 receptor modulation of glutamate re-
lease play a significant role. In fact, most attempts to define a
possible role for P2 receptor modulation of excitatory synaptic
transmission in hippocampal slices essentially concluded that all
the effects of exogenously added ATP or ATP analogs were attrib-
utable to adenosine P1 receptor activation (Dunwiddie et al.,
1997; Cunha et al., 1998; Mendoza-Fernandez et al., 2000; Ma-
sino et al., 2002). This is in agreement with the efficiency of ecto-
nucleotidases in these synapses, which are able to convert ATP
(and ATP analog) into adenosine in a channeling manner
(Cunha et al., 1998) within milliseconds (Dunwiddie et al., 1997),
making it possible to conceive a scenario in which exogenously
added ATP might never reach synaptic P2 receptors before being
degraded by ectonucleotidases (Zimmermann and Braun, 1996).
It should also be pointed out that these electrophysiological stud-
ies were all performed in the same group of glutamatergic syn-
Figure 6. Identification of P2X and P2Y receptors present in rat hippocampal glutamatergic
nerve terminals by double immunocytochemical analysis of rat hippocampal single nerve ter-
minals. In A, as an example, the immunocytochemical identification of P2X3 receptors subunit
(left) in glutamatergic nerve terminals identified as immunopositive for vesicular glutamate
transporters type 1 and type 2 (middle) that comprised 38.6 1.3% (n 3) of the total
synaptosomal population is shown. After merging both images (right), the percentage of rat
hippocampal glutamatergic nerve terminals endowed with each P2X subunit and each P2Y
receptor was quantified, which is presented in B. The data are mean SEM of three or four
experiments, and in each experiment, using different synaptosomal preparation from different
animals, four different fields acquired from two different coverslips were analyzed.
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apses connecting the Schaffer fibers to CA1 pyramidal neurons.
When studying other synapses, it was found that P2X2 receptors
controlled glutamatergic transmission onto interneurons of the
CA1 region (Khakh et al., 2003), P2Y1 receptors controlled inter-
neuron excitability (Kawamura et al., 2004), whereas in mossy
fiber/CA3 pyramid synapses, a mixed P2/P1 modulation by ex-
ogenously added ATP was concluded (Kukley et al., 2004). Thus,
it primarily remains to be tested whether P2 receptors might exert
a more important control of glutamate release in other glutama-
tergic synapses in the hippocampus. A credible alternative might
be that the neuromodulatory role of P2 receptors in glutamater-
gic synapses might not be related to conditions of low-frequency
stimulation, in which one would expect calcium influx through
P2X receptors to be most effective, but might only come into play
during bursts of actions potentials, in which one would expect
this P2 receptor-mediated calcium entry to be overshadowed by
the massive calcium influx and the effect of other facilitating
factor. Accordingly, the most consistent modulatory role of P2
receptors has been found in the control of long-term potentiation
(O’Kane and Stone, 2000, Pankratov et al., 2002; Almeida et al.,
2003). This is also in agreement with the finding that the release of
ATP in hippocampal preparations increases disproportionally
with increasing frequencies of nerve stimulation (Wieraszko et
al., 1989; Cunha et al., 1996).
In conclusion, the present study provided coincident func-
tional and molecular evidences showing that P2 receptors bipha-
sically modulate the release of glutamate from hippocampal
nerve terminals, thus explaining the discrepancy between P2 re-
ceptor expression and detected functional activity in this area of
the brain. The precise physiological conditions under which this
modulation becomes functionally important remain to be
determined.
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